Tell us what you think about Healio
Sign in for a personal experience.
Customized content served to meet your interests.
SAN FRANCISCO — Positive results were found in two pivotal safety and efficacy studies that looked at lurasidone HCl treatment in patients with depressive disorders associated with bipolar I disorder.
In the PREVAIL 1 study, 348 patients with bipolar depression were assigned lurasidone HCl (Latuda, Sunovion Pharmaceuticals; 20 mg/day to 120 mg/day) with or without rapid cycling as adjunctive therapy to lithium or valproate for 6 weeks. Metabolic changes in lipids, glucose, weight and insulin were assessed.
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.
View past polls »
©2013 All Rights Reserved.